Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

From: Allan J. Kvasnicka' [e-mail] [CIGX_VIPGROUP] <[e-mail]>
3:12 PM (14 minutes ago)

to CIGX_VIPGROUP (eMail)

From: Ted Jenkins [mailto:[e-mail]]
Sent: Thursday, July 31, 2014 5:04 PM
To: undisclosed-recipients:
Subject: Today's Rock Creek Press Release

Everyone,
This went out this afternoon. Somewhat of a dichotomy I think, as market volatility not believing we are real. Hopefully, this add’s confidence that we are. Also, not an “either/or” with regard to UK or USA. This is a separate strategy that for the time being is a “duel” initiative, unless we learn otherwise, domestically. Regardless, we should have patients in the clinic this fall, as proposed, in the UK, but hopefully here as well. Regardless, we are moving forward with our strategies and hoping to maintain timelines, regardless. Thought you would be interested.
Best,
Ted

http://www.prnewswire.com/news-releases/rock-creek-pharmaceuticals-provides-update-of-its-european-drug-development-regulatory-strategy-and-selects-quotient-clinical-for-its-early-development-programs-269430631.html


Theodore Jenkins
VP, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals, Inc.
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
[phone] (W)
[phone] (C)
[e-mail]